

Metronidazole Benzoate Compounded Oral Suspension

DEFINITION
Metronidazole Benzoate Compounded Oral Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of metronidazole ($C_6H_9N_3O_3$).

Prepare Metronidazole Benzoate Compounded Oral Suspension containing 50 mg/mL of metronidazole as follows (see [Pharmaceutical Compounding—Nonsterile Preparations \(795\)](#)).

Metronidazole (as the Benzoate) powder	5 g (8 g)
Ora-Blend ^a , a sufficient quantity to make	100 mL

^a Perrigo, Minneapolis, MN.

Place the *Metronidazole Benzoate powder* into a suitable mortar. Wet the powder with a small amount of *Ora-Blend*, and triturate to make a smooth paste. Add the *Ora-Blend* in small portions almost to volume, and mix thoroughly after each addition. Transfer the contents of the mortar, stepwise and quantitatively, to a calibrated container. Add sufficient *Ora-Blend* to bring the preparation to final volume. Shake to mix well.

ASSAY

• **PROCEDURE**

Solution A: 0.1% (v/v) glacial acetic acid in water

Mobile phase: Acetonitrile and *Solution A* (40:60). Filter, and degas.

Standard solution: 0.4 mg/mL of metronidazole prepared from [USP Metronidazole Benzoate RS](#) in *Mobile phase*. Mix well until dissolved.

Sample solution: Shake thoroughly each bottle of Oral Suspension. Transfer 0.8 mL of the Oral Suspension into a 100-mL volumetric flask, dilute with *Mobile phase* to volume, and mix well.

Chromatographic system
(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 316 nm

Column: 4.6-mm × 15-cm; 5-μm packing L1

Column temperature: 30°

Flow rate: 1.0 mL/min

Injection volume: 5 μL

System suitability

Sample: *Standard solution*

[NOTE—The retention time for metronidazole is about 7.7 min.]

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of metronidazole ($C_6H_9N_3O_3$) in the portion of Oral Suspension taken:

Result = $(r_U/r_S) \times (C_S/C_U) \times 100$

r_U = peak response from the *Sample solution*

r_s = peak response from the *Standard solution*

C_s = concentration of metronidazole in the *Standard solution* (mg/mL)

C_u = nominal concentration of metronidazole in the *Sample solution* (mg/mL)

SPECIFIC TESTS

- **pH** (791): 3.6–4.6

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Package in tight, light-resistant containers. Store at 2°–8° or at controlled room temperature.
- **BEYOND-USE DATE:** NMT 90 days after the date on which it was compounded when stored at 2°–8° or controlled room temperature.
- **LABELING:** Label it to indicate that it is to be well-shaken before use, and to state the *Beyond-Use Date*.
- **USP REFERENCE STANDARDS** (11).
[USP Metronidazole Benzoate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METRONIDAZOLE BENZOATE COMPOUNDED ORAL SUSPENSION	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	CMP2020 Compounding 2020

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(4)

Current DocID: GUID-7B80DC10-BF8D-4001-89C7-CDCADE46D1D3_1_en-US

DOI: https://doi.org/10.31003/USPNF_M8094_01_01

DOI ref: [r5i1q](#)

OFFICIAL